Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Pandoraon Feb 08, 2021 9:36pm
152 Views
Post# 32508821

RE:Mr. Li Ka-shing just put 300 Million in WELL at $10 a sha

RE:Mr. Li Ka-shing just put 300 Million in WELL at $10 a shaFor whatever reason the reply & quote functions are not working. Oh well.


Well Health Technologies Corp. has entered into an arrangement agreement to acquire all of the issued and outstanding shares of CRH Medical Corp. at $4 (U.S.) per share in cash representing equity consideration of approximately $292.7-million (U.S.) and a transaction value of approximately $369.2-million (U.S.), inclusive of CRH credit facility. Well has also entered into binding agreements with a group of institutional and individual investors including Li Ka-shing to raise $295.5-million of equity under a non-brokered offering of subscription receipts at a price of $9.80 per share. The offering price represents a 25-per-cent premium to the five-day volume-weighted average price (VWAP) of Well's common shares on the Toronto Stock Exchange preceding this announcement. The proceeds of the offering are expected to be combined with debt facilities provided jointly by Canadian Imperial Bank of Commerce and HSBC Bank Canada as well as Well's existing cash to finance the acquisition. The offering is expected to close in mid-February, 2021, and the acquisition is expected to close in Q2 2021. Completion of the acquisition is subject to regulatory, CRH shareholder and court approvals. The Well common shares to be issued in connection with the offering have received conditional listing approval from the Toronto Stock Exchange. Further details of CRH, the acquisition and offering are set out below.

and from Global:


The Globe and Mail reports in its Monday edition that Well Health Technologies accelerated its acquisition spree on the weekend as it said it would buy fellow Vancouver health-services company CRH Medical for $292.7-million (U.S.). The Globe's Josh O'Kane writes that the company said the deal would be largely financed by a concurrent $295.5-million private placement led by Hong Kong billionaire Li Ka-shing with support from unnamed institutional investors. Well Health added that it would also use some of its cash pile and a line of credit from CIBC and HSBC Holdings PLC. Led by former TIO Networks founder Hamed Shahbazi, Well has amassed a group of 27 health clinics in British Columbia, Quebec and California while building out a network of "allied health" clinics that provides physiotherapy, sleep and other services. It offers digital clinical tools, too, that the company says serves more than 2,200 clinics in North America. In recent months, it has also launched an app marketplace for clinic owners and bought a controlling stake in a U.S. telehealth company, deepening its connections to the North American health-clinic market as the COVID-19 pandemic brings increased attention to health-technology companies.

© 2021 Canjex Publishing Ltd. All rights reserved.


<< Previous
Bullboard Posts
Next >>